CY1121345T1 - Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης - Google Patents
Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσηςInfo
- Publication number
- CY1121345T1 CY1121345T1 CY20191100279T CY191100279T CY1121345T1 CY 1121345 T1 CY1121345 T1 CY 1121345T1 CY 20191100279 T CY20191100279 T CY 20191100279T CY 191100279 T CY191100279 T CY 191100279T CY 1121345 T1 CY1121345 T1 CY 1121345T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lysosomic
- pharmaceutical compositions
- storage disorders
- addressed
- uses addressed
- Prior art date
Links
- 230000001868 lysosomic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 2
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 abstract 1
- 229960000669 acetylleucine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613828.1A GB201613828D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for lysosomal storage disorders |
| GBGB1702552.9A GB201702552D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for lysosomal storage disorders |
| GBGB1705762.1A GB201705762D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for lysosomal storage disorders |
| GBGB1706854.5A GB201706854D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for lysosomal storage disorders |
| PCT/IB2017/054928 WO2018029657A1 (en) | 2016-08-11 | 2017-08-11 | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121345T1 true CY1121345T1 (el) | 2020-05-29 |
Family
ID=59859423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100279T CY1121345T1 (el) | 2016-08-11 | 2019-03-08 | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης |
| CY20211100017T CY1123844T1 (el) | 2016-08-11 | 2021-01-12 | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100017T CY1123844T1 (el) | 2016-08-11 | 2021-01-12 | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US11400067B2 (https=) |
| EP (4) | EP3482754B1 (https=) |
| JP (4) | JP7393943B2 (https=) |
| KR (4) | KR20220154849A (https=) |
| CN (3) | CN109843275B (https=) |
| AU (3) | AU2017308864B2 (https=) |
| CA (1) | CA3033557A1 (https=) |
| CY (2) | CY1121345T1 (https=) |
| DK (2) | DK3359146T3 (https=) |
| ES (2) | ES2849566T3 (https=) |
| FI (1) | FIC20260014I1 (https=) |
| HK (1) | HK1253282B (https=) |
| HR (2) | HRP20190344T1 (https=) |
| HU (2) | HUE052837T2 (https=) |
| IL (2) | IL314107A (https=) |
| LT (2) | LT3482754T (https=) |
| MA (2) | MA43876B1 (https=) |
| MD (2) | MD3359146T2 (https=) |
| ME (1) | ME03340B (https=) |
| MX (2) | MX384447B (https=) |
| NZ (3) | NZ790895A (https=) |
| PL (2) | PL3482754T3 (https=) |
| PT (2) | PT3482754T (https=) |
| RS (2) | RS61442B1 (https=) |
| RU (1) | RU2749515C2 (https=) |
| SG (1) | SG11201901048VA (https=) |
| SI (2) | SI3359146T1 (https=) |
| SM (2) | SMT202100050T1 (https=) |
| TN (1) | TN2019000032A1 (https=) |
| WO (1) | WO2018029657A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3359146T3 (en) * | 2016-08-11 | 2019-04-08 | Intrabio Ltd | PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| EP3886986A1 (en) * | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Deuterated analogs of acetyl-leucine |
| SMT202400334T1 (it) * | 2019-03-02 | 2024-09-16 | Intrabio Ltd | (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche |
| RS67283B1 (sr) | 2019-06-28 | 2025-11-28 | Intrabio Ltd | Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2749512B1 (fr) * | 1996-06-10 | 1999-08-13 | Pf Medicament | Utilisation de l'acetyl dl leucine pour le traitement des tremblements |
| AU2001269923A1 (en) | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| FR2883180B1 (fr) | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| FR2905600B1 (fr) | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| WO2009114729A2 (en) * | 2008-03-14 | 2009-09-17 | Irm Llc | Compounds, compositions and methods for treating lysosomal storage diseases and disorders |
| TN2010000251A1 (fr) | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| TN2010000566A1 (en) | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| GB201114017D0 (en) | 2011-08-15 | 2011-09-28 | Univ Dundee | Inhibitors against endosomal/ysosomal enzymes |
| JP2015518872A (ja) | 2012-06-06 | 2015-07-06 | フォンダッツィオーネ・テレソン | アロステリックシャペロンおよびその使用 |
| KR102247701B1 (ko) | 2016-02-26 | 2021-05-03 | 한미정밀화학주식회사 | 폴리에틸렌글리콜 디알데히드 유도체의 제조방법 |
| WO2018029658A1 (en) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| DK3359146T3 (en) | 2016-08-11 | 2019-04-08 | Intrabio Ltd | PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES |
-
2017
- 2017-08-11 DK DK17767933.9T patent/DK3359146T3/en active
- 2017-08-11 KR KR1020227039341A patent/KR20220154849A/ko not_active Ceased
- 2017-08-11 RU RU2019106493A patent/RU2749515C2/ru active
- 2017-08-11 EP EP18210763.1A patent/EP3482754B1/en active Active
- 2017-08-11 KR KR1020227009897A patent/KR102467953B1/ko active Active
- 2017-08-11 IL IL314107A patent/IL314107A/en unknown
- 2017-08-11 SG SG11201901048VA patent/SG11201901048VA/en unknown
- 2017-08-11 NZ NZ790895A patent/NZ790895A/en unknown
- 2017-08-11 RS RS20210064A patent/RS61442B1/sr unknown
- 2017-08-11 ES ES18210763T patent/ES2849566T3/es active Active
- 2017-08-11 SI SI201730032T patent/SI3359146T1/sl unknown
- 2017-08-11 PT PT182107631T patent/PT3482754T/pt unknown
- 2017-08-11 JP JP2019507811A patent/JP7393943B2/ja active Active
- 2017-08-11 ES ES17767933T patent/ES2716133T3/es active Active
- 2017-08-11 NZ NZ790894A patent/NZ790894A/en unknown
- 2017-08-11 SM SM20210050T patent/SMT202100050T1/it unknown
- 2017-08-11 HK HK18112571.2A patent/HK1253282B/en unknown
- 2017-08-11 IL IL264610A patent/IL264610B2/en unknown
- 2017-08-11 HR HRP20190344TT patent/HRP20190344T1/hr unknown
- 2017-08-11 WO PCT/IB2017/054928 patent/WO2018029657A1/en not_active Ceased
- 2017-08-11 MA MA43876A patent/MA43876B1/fr unknown
- 2017-08-11 KR KR1020247021734A patent/KR20240110078A/ko active Pending
- 2017-08-11 PT PT17767933T patent/PT3359146T/pt unknown
- 2017-08-11 DK DK18210763.1T patent/DK3482754T3/da active
- 2017-08-11 SM SM20190154T patent/SMT201900154T1/it unknown
- 2017-08-11 RS RS20190334A patent/RS58478B1/sr unknown
- 2017-08-11 PL PL18210763T patent/PL3482754T3/pl unknown
- 2017-08-11 CN CN201780062740.XA patent/CN109843275B/zh active Active
- 2017-08-11 LT LTEP18210763.1T patent/LT3482754T/lt unknown
- 2017-08-11 EP EP17767933.9A patent/EP3359146B1/en active Active
- 2017-08-11 LT LTEP17767933.9T patent/LT3359146T/lt unknown
- 2017-08-11 MA MA055947A patent/MA55947A/fr unknown
- 2017-08-11 HU HUE18210763A patent/HUE052837T2/hu unknown
- 2017-08-11 CA CA3033557A patent/CA3033557A1/en active Pending
- 2017-08-11 SI SI201730613T patent/SI3482754T1/sl unknown
- 2017-08-11 ME MEP-2019-60A patent/ME03340B/me unknown
- 2017-08-11 MD MDE20181131T patent/MD3359146T2/ro unknown
- 2017-08-11 MD MDE20190593T patent/MD3482754T2/ro unknown
- 2017-08-11 EP EP24154769.4A patent/EP4342461A3/en active Pending
- 2017-08-11 TN TNP/2019/000032A patent/TN2019000032A1/en unknown
- 2017-08-11 CN CN202511761192.2A patent/CN121360107A/zh active Pending
- 2017-08-11 KR KR1020197007024A patent/KR102412724B1/ko active Active
- 2017-08-11 MX MX2019001577A patent/MX384447B/es unknown
- 2017-08-11 HU HUE17767933A patent/HUE041914T2/hu unknown
- 2017-08-11 AU AU2017308864A patent/AU2017308864B2/en active Active
- 2017-08-11 NZ NZ750391A patent/NZ750391A/en unknown
- 2017-08-11 PL PL17767933T patent/PL3359146T3/pl unknown
- 2017-08-11 US US16/324,301 patent/US11400067B2/en active Active
- 2017-08-11 CN CN202511761193.7A patent/CN121360108A/zh active Pending
- 2017-08-11 EP EP20215877.0A patent/EP3865126A1/en active Pending
-
2019
- 2019-02-07 MX MX2021008432A patent/MX2021008432A/es unknown
- 2019-03-08 CY CY20191100279T patent/CY1121345T1/el unknown
-
2021
- 2021-01-12 CY CY20211100017T patent/CY1123844T1/el unknown
- 2021-01-29 HR HRP20210153TT patent/HRP20210153T1/hr unknown
-
2022
- 2022-01-07 JP JP2022001694A patent/JP2022050564A/ja active Pending
- 2022-06-30 US US17/854,027 patent/US12433862B2/en active Active
-
2023
- 2023-05-10 AU AU2023202903A patent/AU2023202903B2/en active Active
-
2024
- 2024-02-02 US US18/430,858 patent/US12433863B2/en active Active
- 2024-02-27 JP JP2024027864A patent/JP7757446B2/ja active Active
-
2025
- 2025-05-14 AU AU2025203479A patent/AU2025203479A1/en active Pending
- 2025-08-06 US US19/292,431 patent/US20260027077A1/en active Pending
- 2025-10-08 JP JP2025170034A patent/JP2025188157A/ja active Pending
-
2026
- 2026-04-27 FI FIC20260014C patent/FIC20260014I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125193T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν μελοξικαμη | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
| CY1121930T1 (el) | Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες | |
| CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| JOP20170107B1 (ar) | مشتقات سلفوناميد عطرية | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| MX2016012262A (es) | Cenicriviroc para el tratamiento de fibrosis. | |
| MX2017016806A (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina. | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| BR112017028140A2 (pt) | formulações farmacêuticas | |
| EA202191114A1 (ru) | Производные пиридинилсульфонамида, фармацевтические композиции и их применение | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| CY1124967T1 (el) | Παραγωγα αμινοπυριδινης και χρηση αυτων ως εκλεκτικοι αναστολεις alk-2 | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
| EA201790893A1 (ru) | Способы лечения офтальмологических расстройств |